Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: A propensity score-matched study

Ilya Kister, Tim Spelman, Raed Alroughani, Jeannette Lechner-Scott, Pierre Duquette, Francois Grand'Maison, Mark Slee, Alessandra Lugaresi, Michael Barnett, Pierre Grammond, Gerardo Iuliano, Raymond Hupperts, Eugenio Pucci, Maria Trojano, Helmut Butzkueven

Research output: Contribution to journalArticle

Abstract

Background Discontinuation of injectable diseasemodifying therapy (DMT) for multiple sclerosis (MS) after a long period of relapse freedom is frequently considered, but data on post-cessation disease course are lacking. Objectives (1) To compare time to first relapse and disability progression among 'DMT stoppers' and propensity-score matched 'DMT stayers' in the MSBase Registry; (2) To identify predictors of time to first relapse and disability progression in DMT stoppers. Methods Inclusion criteria for DMT stoppers were: age ≥18 years; no relapses for ≥5 years at DMT discontinuation; follow-up for ≥3 years after stopping DMT; not restarting DMT for ≥3 months after discontinuation. DMT stayers were required to have no relapses for ≥5 years at baseline, and were propensityscore matched to stoppers for age, sex, disability (Expanded Disability Status Score), disease duration and time on treatment. Relapse and disability progression events in matched stoppers and stayers were compared using a marginal Cox model. Predictors of first relapse and disability progression among DMT stoppers were investigated using a Cox proportional hazards model. Results Time to first relapse among 485 DMT stoppers and 854 stayers was similar (adjusted HR, aHR=1.07, 95% CI 0.84 to 1.37; p=0.584), while time to confirmed disability progression was significantly shorter among DMT stoppers than stayers (aHR=1.47, 95% CI 1.18 to 1.84, p=0.001). The difference in hazards of progression was due mainly to patients who had not experienced disability progression in the prebaseline treatment period. Conclusions Patients with MS who discontinued injectable DMT after a long period of relapse freedom had a similar relapse rate as propensity score-matched patients who continued on DMT, but higher hazard for disability progression.

Original languageEnglish
Pages (from-to)1133-1137
Number of pages5
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume87
Issue number10
DOIs
Publication statusPublished - Oct 1 2016

ASJC Scopus subject areas

  • Surgery
  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: A propensity score-matched study'. Together they form a unique fingerprint.

  • Cite this

    Kister, I., Spelman, T., Alroughani, R., Lechner-Scott, J., Duquette, P., Grand'Maison, F., Slee, M., Lugaresi, A., Barnett, M., Grammond, P., Iuliano, G., Hupperts, R., Pucci, E., Trojano, M., & Butzkueven, H. (2016). Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: A propensity score-matched study. Journal of Neurology, Neurosurgery and Psychiatry, 87(10), 1133-1137. https://doi.org/10.1136/jnnp-2016-313760